DiscGenics' injectable disc cell therapy passed an initial planned safety review of its Phase I/II trial for the treatment of mild to moderate degenerative disc disease.
LimaCorporate and the Hospital for Special Surgery are co-founding an additive manufacturing 3D printing facility to create custom orthopaedic implants in a hospital setting.
SpineEx, developer of an expandable device for minimally invasive lateral lumbar interbody fusion, withdrew its plans for a US $17MM initial public offering late in 4Q18.
Episurf Medical received another Notice of Allowance from the USPTO, addressing image segmentation used for 3D joint damage visualization as well as the design of patient-specific implants and instruments.
Histogenics plans to evaluate the range of potential strategic alternatives for its NeoCart® cell therapy following FDA's indication that an additional clinical trial would be required before acceptance of a Biologics License Application submission.
JointPoint obtained Health Canada licenses for ELITE and PRO surgical navigation systems, allowing for immediate deployment of these products in the region.